D. Ripamonti

发表

Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial

Annapaola Callegaro, F. Maggiolo, D. Ripamonti, 2004, AIDS.

CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART.

Annapaola Callegaro, F. Maggiolo, D. Ripamonti, 2009, AIDS.

Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support

Jonathan H. Morgan, F. Landi, F. Di Marco, 2020, medRxiv.

Ageing with HIV: a multidisciplinary review

A. Calcagno, A. Riva, D. Ripamonti, 2015, Infection.

Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.

G. di Perri, A. Calcagno, G. Cenderello, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Limited sampling strategies for the estimation of atazanavir daily exposure in HIV‐infected patients

E. Clementi, D. Cattaneo, D. Ripamonti, 2013, Fundamental & clinical pharmacology.

Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort.

F. Maggiolo, D. Ripamonti, F. Suter, 2007, The Journal of antimicrobial chemotherapy.

The changing pattern of bacterial and fungal respiratory isolates in patients with and without COVID-19 admitted to intensive care unit

C. Farina, D. Ripamonti, M. Rizzi, 2022, BMC Infectious Diseases.

The Changing Pattern of Bacterial and Fungal Respiratory Isolates in Patients with COVID-19 Admitted to Intensive Care Unit

C. Farina, D. Ripamonti, M. Rizzi, 2021 .

A first update on mapping the human genetic architecture of COVID-19

Eurie L. Hong, E. F. Perez, Rachel G Liao, 2022, Nature.

Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases.

P. Sarzi-Puttini, R. Scrivo, F. D. De Rosa, 2020, Clinical and experimental rheumatology.

Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial

A. Antinori, D. Ripamonti, P. Girard, 2017, HIV medicine.

Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?

D. Ripamonti, A. Hill, C. Moecklinghoff, 2013, AIDS reviews.

Autoimmune hepatitis and HIV infection: two case reports and review of the literature.

D. Ripamonti, M. Rizzi, L. Comí, 2017, AIDS.

Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection–Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study

G. d’Ettorre, A. Antinori, C. Mussini, 2020, Pathogens & immunity.

Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy

A. Giacomelli, G. d’Ettorre, M. Capobianchi, 2022, Sexually transmitted infections.

Hepatitis C infection increases the risk of the modification of first highly active antiretroviral therapy in HIV-infected patients

P. Pezzotti, F. Maggiolo, D. Ripamonti, 2004, AIDS.

Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV‐Infected Patients

E. Clementi, D. Cattaneo, D. Ripamonti, 2012, Journal of clinical pharmacology.

E. Clementi, D. Cattaneo, D. Ripamonti, 2010, Therapeutic drug monitoring.

Resolution of Lymphocytic Interstitial Pneumonia in a Human Immunodeficiency Virus-infected Adult Following the Start of Highly Active Antiretroviral Therapy

M. Rízzí, F. Maggiolo, D. Ripamonti, 2003, Scandinavian journal of infectious diseases.

Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues

B. Clotet, A. Antinori, A. Clarke, 2015, AIDS.

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer

D. Cattaneo, F. Maggiolo, D. Ripamonti, 2007, AIDS.

HIV regimens de-intensification with PI monotherapy: one size does not fit all

D. Ripamonti, 2012 .

Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection.

F. Maggiolo, D. Ripamonti, A. Callegaro, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Combination Antifungal Therapy for Invasive Aspergillosis

R. Barbó, L. Barozzi, D. Ripamonti, 2005 .

Reply to Nucci and Anaissie

R. Barbó, D. Ripamonti, F. Suter, 2005 .

Pyogenic Vertebral Osteomyelitis in Adults: Ten-year Experience in Two Italian Hospitals

T. Santantonio, D. Ripamonti, V. Ravasio, 2019 .

HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications.

M. Andreoni, D. Ripamonti, A. Giacometti, 2012, European review for medical and pharmacological sciences.

Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature.

D. Ripamonti, V. Ravasio, M. Rizzi, 2014, AIDS.

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

C. Mussini, F. Maggiolo, D. Ripamonti, 2017, BMC Infectious Diseases.

HIV-1 and hepatitis B virus: time for a re-think?

F. Maggiolo, D. Ripamonti, F. Suter, 2004, The Lancet.

Hepatitis C Infection Influence on Immune Recovery in HIV-Positive Patients on Successful HAART: The Role of Genotype 3

C. Tinelli, R. Maserati, E. Seminari, 2010 .

Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort

S. Leone, F. Maggiolo, D. Ripamonti, 2011, Infection.

Severe Hepatotoxicity During Combination Antiretroviral Treatment: Incidence, Liver Histology, and Outcome

F. Callea, F. Castelli, C. Torti, 2003, Journal of acquired immune deficiency syndromes.

Switch strategies in patients on effective HAART.

F. Maggiolo, D. Ripamonti, F. Suter, 2005, The Journal of antimicrobial chemotherapy.

Simpler Regimens May Enhance Adherence to Antiretrovirals in HIV-Infected Patients

F. Maggiolo, D. Ripamonti, F. Suter, 2002, HIV clinical trials.

Once-A-Day Therapy for HIV Infection: A Controlled, Randomized Study in Antiretroviral-Naive HIV-1-Infected Patients

F. Maggiolo, D. Ripamonti, G. Gregis, 2002, Antiviral therapy.

Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor

D. Ripamonti, M. Rizzi, E. Bombana, 2014, Expert review of anti-infective therapy.

F. Maggiolo, D. Ripamonti, F. Suter, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Once-a-Day HAART: Dream or Reality?

F. Maggiolo, D. Ripamonti, F. Suter, 2003, HIV clinical trials.

Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.

M. Prosperi, I. Frank, C. Torti, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART

F. Maggiolo, D. Ripamonti, G. Quinzan, 2001, International journal of STD & AIDS.

Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort.

G. d’Ettorre, C. Mussini, A. Cingolani, 2020, HIV medicine.

Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study).

R. Maserati, A. Lazzarin, S. Lo Caputo, 2016, The new microbiologica.

Estimating duration of HIV infection with CD4 cell count and HIV-1 RNA at presentation.

A. d’Arminio Monforte, G. Ippolito, D. Serraino, 2001, AIDS.

Mapping the human genetic architecture of COVID-19

Mattia G. Bergomi, Christopher M. DeBoever, Matthew A. Wiles, 2021, Nature.

Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19

Jonathan H. Morgan, A. Mantovani, F. Di Marco, 2021, Leukemia.

Treatment of primary effusion lymphoma with highly active antiviral therapy in the setting of HIV infection.

A. Rambaldi, D. Ripamonti, F. Suter, 2008, AIDS.

Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution

F. Maggiolo, D. Ripamonti, F. Suter, 2001, International journal of STD & AIDS.

African sleeping sickness in tourists returning from Tanzania: the first 2 Italian cases from a small outbreak among European travelers.

M. Massari, C. Farina, D. Ripamonti, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

New times for an old disease: intracranial mass lesions caused by Mycobacterium tuberculosis in 5 HIV-negative African immigrants.

R. Barbó, D. Ripamonti, F. Suter, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Factors associated with the failure of HIV-positive persons to return for scheduled medical visits

P. Pezzotti, F. Maggiolo, D. Ripamonti, 2002, HIV clinical trials.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study

M. Fabbiani, E. Quiros-Roldan, G. Lapadula, 2022, Medicine.

Association of the HLA-B*53: 01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir

E. Phillips, D. Ostrov, P. Loulergue, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Transplacental passage of ritonavir-boosted darunavir in two pregnant women

D. Cattaneo, F. Maggiolo, D. Ripamonti, 2009, International journal of STD & AIDS.

Steady State Pharmacokinetic of Ritonavir-boosted Atazanavir in 31 Pregnant Women before and after Delivery.

D. Cattaneo, F. Maggiolo, D. Ripamonti, 2010 .

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?

C. Viscoli, N. Riccardi, L. Taramasso, 2017, AIDS Research and Human Retroviruses.

PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection

R. Maserati, G. Nunnari, C. Sagnelli, 2017, PloS one.

An explainable model of host genetic interactions linked to COVID-19 severity

G. Parati, A. d’Arminio Monforte, F. Chiaromonte, 2021, Communications Biology.

Salvage Therapy with Abacavir in HIV-1-Infected Patients with Previously Documented M184V Mutation: A Possibility of Nrti Recycling

A. Goglio, F. Maggiolo, D. Ripamonti, 2002, Antiviral therapy.

Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting.

F. Castelli, L. Leone, C. Torti, 2003, Health policy.

Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality

R. Haubrich, R. Bruno, A. Chokkalingam, 2021, Open forum infectious diseases.

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study

A. d’Arminio Monforte, R. Maserati, A. Antinori, 2020, Journal of acquired immune deficiency syndromes.

Prediction of Virologic Outcome of Salvage Antiretroviral Treatment by Different Systems for Interpreting Genotypic HIV Drug Resistance

F. Maggiolo, D. Ripamonti, A. Callegaro, 2007, Journal of the International Association of Physicians in AIDS Care.

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

F. Montagnini, M. Giacomini, G. Innocenti, 2020, Journal of Translational Medicine.

Unboosted Atazanavir for Treatment of HIV Infection

C. Torti, D. Ripamonti, D. Motta, 2012, Drugs.

SARS‐CoV‐2 infection in persons living with HIV: A single center prospective cohort

M. Arosio, F. Maggiolo, D. Ripamonti, 2020, Journal of medical virology.

Predictors of HIV RNA Suppression on Darunavir/Ritonavir Monotherapy or Triple Therapy in the MONET and PROTEA Trials

D. Ripamonti, A. Hill, R. Demasi, 2015 .

Strategic selective treatment in highly pre-treated HIV patients harbouring multiply resistant viruses.

A. Goglio, F. Maggiolo, D. Ripamonti, 2002, AIDS.

Vascular graft infections caused by Mycobacterium bovis BCG after BCG immunotherapy for non-muscle-invasive bladder cancer: Case report and review of literature

M. Arosio, C. Farina, D. Ripamonti, 2023, Journal of clinical tuberculosis and other mycobacterial diseases.

Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy–Experienced Patients: A Multicenter Clinical Experience

A. d’Arminio Monforte, G. Marchetti, P. Cicconi, 2014, HIV clinical trials.

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study

Jonathan H. Morgan, F. Di Marco, G. Gritti, 2020 .

Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.

F. Maggiolo, D. Ripamonti, 2008, Current opinion in investigational drugs.

The Effect of HIV-1 Resistance Mutations after First-Line Virological Failure on the Possibility to Sequence Antiretroviral Drugs in Second-Line Regimens

A. Antinori, L. Minoli, C. Torti, 2006, Antiviral therapy.

Abacavir-induced liver toxicity in an HIV-infected patient.

D. Ripamonti, M. Rizzi, E. di Filippo, 2014, AIDS.

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial

P. Ascierto, M. Massari, M. Costantini, 2020, medRxiv.

Resistance Costs and Future Drug Options of Antiretroviral Therapies: Analysis of the Role of NRTIs, NNRTIs, and PIs in a Large Clinical Cohort

A. Goglio, F. Maggiolo, D. Ripamonti, 2007, HIV clinical trials.

Changing patterns of HIV transmission and better targeting for intervention strategies

G. Carosi, D. Ripamonti, G. Paraninfo, 1998, International journal of STD & AIDS.

Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection.

N. Perico, D. Cattaneo, F. Maggiolo, 2008, Journal of chromatographic science.

Discordant immunological response in HIV-positive patients on non-nucleoside reverse transcriptase inhibitor-based regimens.

F. Maggiolo, D. Ripamonti, F. Suter, 2002, AIDS (London).

Pediatric risk of mortality: an assessment of its performance in a sample of 26 Italian intensive care units.

G. Apolone, G. Bertolini, D. Ripamonti, 1998, Critical care medicine.

Cutaneous mucormycosis by Rhizopus arrhizus treated with isavuconazole as first line therapy: A case report

D. Ripamonti, M. Rizzi, A. Tebaldi, 2019, Medical mycology case reports.

Mapping the human genetic architecture of COVID-19

Mattia G. Bergomi, Christopher M. DeBoever, Matthew A. Wiles, 2021, Nature.

Do lopinavir and ritonavir require a dose adjustment during pregnancy?

D. Cattaneo, D. Ripamonti, 2014, Journal of Acquired Immune Deficiency Syndromes.

Mapping the human genetic architecture of COVID-19

Eurie L. Hong, E. F. Perez, Rachel G Liao, 2021 .

Author response: Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study

E. Martinelli, G. Parati, R. Scala, 2021 .